REDWOOD CITY, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced several virtual presentations of data from the company’s gene therapy programs in May 2020.
American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting 2020
Abstracts are available online and presentations and posters can be accessed through ASGCT’s website on May 12, 2020 at www.asgct.org.
Abstract Title (Oral): ADVM-022 Intravitreal Gene Therapy for Neovascular AMD - Results from the Phase 1 OPTIC Study
Session: AAV Vectors - Clinical Studies II
Date/Time: Wednesday, May 13, 2020, 4:00 - 4:15 pm EDT
Speaker: Szilárd Kiss, M.D., Director of Clinical Research in the Department of Ophthalmology at Weill Cornell Medical Group
Abstract Title (Poster): Proof-of-Concept Studies in Mongolian Gerbils Support Intravitreal Gene Replacement Therapy of Human L-Opsin for Blue Cone Monochromacy
Session: AAV Vectors - Preclinical and Proof-of-Concept Studies
Date/Time: Wednesday, May 13, 2020, 5:30 - 6:30 pm EDT
Abstract Title (Poster): Large Scale Suspension Production of AAV Capsid Variant Libraries from Stable Recombinant HEK293 Cell Banks
Session: Vector and Cell Engineering, Production or Manufacturing
Date/Time: Tuesday May 12, 2020, 5:30 - 6:30 pm EDT
Association for Vision and Ophthalmology (ARVO)
The ARVO 2020 Annual Meeting has been cancelled and video-recorded presentations will be available online on ARVOLearn beginning May 16, 2020. Additionally, abstracts will be published in the journal Investigative Ophthalmology & Vision Science (IOVS) no later than July 31, 2020.
Abstract Title: Intravitreal Delivery of AAV2.7m8. Ranibizumab Suppresses Exudative Lesions in the NHP Laser Induced Model of nAMD
Abstract Title: Mouse Studies Support Intravitreal Gene Therapy for Blue Cone Monochromacy
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Investors:
Myesha Lacy
Adverum Biotechnologies, Inc.
mlacy@adverum.com
1-650-649-1257
Media:
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com
1-646-876-5196
Source: Adverum Biotechnologies, Inc.